232 related articles for article (PubMed ID: 21328522)
1. Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group.
Naranjo A; Parisi MT; Shulkin BL; London WB; Matthay KK; Kreissman SG; Yanik GA
Pediatr Blood Cancer; 2011 Jul; 56(7):1041-5. PubMed ID: 21328522
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma.
Hero B; Hunneman DH; Gahr M; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):220-3. PubMed ID: 11464889
[TBL] [Abstract][Full Text] [Related]
3. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.
Yanik GA; Parisi MT; Shulkin BL; Naranjo A; Kreissman SG; London WB; Villablanca JG; Maris JM; Park JR; Cohn SL; McGrady P; Matthay KK
J Nucl Med; 2013 Apr; 54(4):541-8. PubMed ID: 23440556
[TBL] [Abstract][Full Text] [Related]
4. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma.
Matthay KK; Edeline V; Lumbroso J; Tanguy ML; Asselain B; Zucker JM; Valteau-Couanet D; Hartmann O; Michon J
J Clin Oncol; 2003 Jul; 21(13):2486-91. PubMed ID: 12829667
[TBL] [Abstract][Full Text] [Related]
5. Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma.
Mazloom A; Louis CU; Nuchtern J; Kim E; Russell H; Allen-Rhoades W; Krance R; Paulino AC
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):858-62. PubMed ID: 25245583
[TBL] [Abstract][Full Text] [Related]
6. Treatment of advanced neuroblastoma in children over 1 year of age: the critical role of ¹³¹I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen.
Mastrangelo S; Rufini V; Ruggiero A; Di Giannatale A; Riccardi R
Pediatr Blood Cancer; 2011 Jul; 56(7):1032-40. PubMed ID: 21344615
[TBL] [Abstract][Full Text] [Related]
7. Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma.
Katzenstein HM; Cohn SL; Shore RM; Bardo DM; Haut PR; Olszewski M; Schmoldt J; Liu D; Rademaker AW; Kletzel M
J Clin Oncol; 2004 Oct; 22(19):3909-15. PubMed ID: 15459212
[TBL] [Abstract][Full Text] [Related]
8. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study.
Decarolis B; Schneider C; Hero B; Simon T; Volland R; Roels F; Dietlein M; Berthold F; Schmidt M
J Clin Oncol; 2013 Mar; 31(7):944-51. PubMed ID: 23341514
[TBL] [Abstract][Full Text] [Related]
9. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy.
Kushner BH; Yeh SD; Kramer K; Larson SM; Cheung NK
J Clin Oncol; 2003 Mar; 21(6):1082-6. PubMed ID: 12637474
[TBL] [Abstract][Full Text] [Related]
10. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.
Schmidt M; Simon T; Hero B; Schicha H; Berthold F
Eur J Cancer; 2008 Jul; 44(11):1552-8. PubMed ID: 18424129
[TBL] [Abstract][Full Text] [Related]
11. Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.
Yanik GA; Parisi MT; Naranjo A; Nadel H; Gelfand MJ; Park JR; Ladenstein RL; Poetschger U; Boubaker A; Valteau-Couanet D; Lambert B; Castellani MR; Bar-Sever Z; Oudoux A; Kaminska A; Kreissman SG; Shulkin BL; Matthay KK
J Nucl Med; 2018 Mar; 59(3):502-508. PubMed ID: 28887399
[TBL] [Abstract][Full Text] [Related]
12. Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system.
Suc A; Lumbroso J; Rubie H; Hattchouel JM; Boneu A; Rodary C; Robert A; Hartmann O
Cancer; 1996 Feb; 77(4):805-11. PubMed ID: 8616776
[TBL] [Abstract][Full Text] [Related]
13. Persistent positive metaiodobenzylguanidine scans after autologous peripheral blood stem cell transplantation may indicate maturation of stage 4 neuroblastoma.
Okamoto Y; Kodama Y; Nishikawa T; Rindiarti A; Tanabe T; Nakagawa S; Yoshioka T; Takumi K; Kaji T; Kawano Y
Pediatr Hematol Oncol; 2017 Apr; 34(3):157-164. PubMed ID: 28976242
[TBL] [Abstract][Full Text] [Related]
14. Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group.
Streby KA; Parisi MT; Shulkin BL; LaBarre B; Bagatell R; Diller L; Grupp SA; Matthay KK; Voss SD; Yu AL; London WB; Park JR; Yanik GA; Naranjo A
Pediatr Blood Cancer; 2023 Aug; 70(8):e30418. PubMed ID: 37199022
[TBL] [Abstract][Full Text] [Related]
15. MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
DuBois SG; Mody R; Naranjo A; Van Ryn C; Russ D; Oldridge D; Kreissman S; Baker DL; Parisi M; Shulkin BL; Bai H; Diskin SJ; Batra V; Maris JM; Park JR; Matthay KK; Yanik G
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28383813
[TBL] [Abstract][Full Text] [Related]
16. Incorporation of high-dose
Lee JW; Lee S; Cho HW; Ma Y; Yoo KH; Sung KW; Koo HH; Cho EJ; Lee SK; Lim DH
J Hematol Oncol; 2017 May; 10(1):108. PubMed ID: 28511709
[TBL] [Abstract][Full Text] [Related]
17. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
18. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.
Ladenstein R; Lambert B; Pötschger U; Castellani MR; Lewington V; Bar-Sever Z; Oudoux A; Śliwińska A; Taborska K; Biassoni L; Yanik GA; Naranjo A; Parisi MT; Shulkin BL; Nadel H; Gelfand MJ; Matthay KK; Park JR; Kreissman SG; Valteau-Couanet D; Boubaker A
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):292-305. PubMed ID: 28940046
[TBL] [Abstract][Full Text] [Related]
19. Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. The SFOP Group.
Frappaz D; Bonneu A; Chauvot P; Edeline V; Giammarile F; Siles S; Wioland M; Gomez F
Med Pediatr Oncol; 2000 Apr; 34(4):237-41. PubMed ID: 10742058
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma.
Messina JA; Cheng SC; Franc BL; Charron M; Shulkin B; To B; Maris JM; Yanik G; Hawkins RA; Matthay KK
Pediatr Blood Cancer; 2006 Dec; 47(7):865-74. PubMed ID: 16444675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
